10+ Emerging Markets, Japan & ANZ Transition in Final Phase
Bengaluru, India: December 18, 2023
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced the successful completion of the transition of the acquired biosimilars business in ~120 countries across Advanced and Emerging Markets, a year ahead of schedule.
Over 10 Emerging Markets along with Japan, Australia and New Zealand have transitioned in this final phase of the integration of the biosimilars business acquired from Viatris. With the completion of this significant milestone, Biocon Biologics is now a unique, fully integrated ‘lab to market’ biosimilars company committed to serving millions of patients across the globe.
Earlier in 2023, over 70 Emerging Markets were integrated in July, the North America business transitioned in September and the European business in November.
Biocon Biologics has made several key leadership appointments, built new capabilities and infrastructure from the ground up and set up dedicated teams to address the growing needs of patients and customers through self-led and partner or distributor-led commercial models.
Biocon Biologics will now have a strong commercial footprint across ~120 countries with a direct presence in the United States, Canada, Europe and 9 key Emerging Market countries, namely India, UAE, Saudi Arabia, Morocco, South Africa, Brazil, Malaysia, Thailand, and the Philippines.
All Viatris’ biosimilar brands, including Ogivri® & Hertraz® (bTrastuzumab), Abevmy® (bBevacizumab), Fulphila® (bPegfilgrastim), Hulio® (bAdalimumab), Nepexto® (bEtanercept), Semglee® (bGlargine) and Kirsty® (bAspart), will now be marketed by Biocon Biologics teams, ensuring business continuity for patients, prescribers, partners, and healthcare systems. Most of these products have been developed by Biocon Biologics and are being manufactured at the Company’s world-class facilities in India and Malaysia. The diverse portfolio covers key therapeutic areas of diabetology, oncology and immunology.
A direct presence in these markets will enable the Company to get closer to patients and strengthen its relationships with prescribers and payers. It will also allow Biocon Biologics to expand its patient reach and generate significant savings for healthcare systems.
Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, said: “I am very proud and excited that we have successfully completed the integration of the acquired business across 120 countries. The conclusion of this final wave of transition is a significant milestone and marks the beginning of Biocon Biologics’ transformation to a fully integrated global company. I congratulate and thank the entire Biocon Biologics team – colleagues, advisors, and partners. This seamless transition, achieved ahead of schedule, is an outcome of relentless focus, untiring efforts and an unwavering commitment to patients and business continuity.”
Matthew Erick, Chief Commercial Officer – Advanced Markets, Biocon Biologics Ltd, said: “We are extremely pleased to have reached this historic moment and are proud to say that biosimilars are not just what we do – they are all that we do. With the successful completion of the integration, we will be providing patients, customers, and healthcare providers in North America, Europe and JANZ a strong portfolio of biosimilars. Our deep expertise, commitment to continual investment to advance biosimilars throughout the value chain from development, manufacturing, distribution and commercialization makes us a trusted partner.”
Susheel Umesh, Chief Commercial Officer – Emerging Markets, Biocon Biologics said: “The completion of the integration marks a key milestone in Biocon Biologics’ transformational journey towards becoming a global biosimilars leader. This presents a unique opportunity for our teams to take Brand Biocon Biologics directly to many markets. This self-led business model in key Emerging Markets will take us closer to patients, MoHs, prescribers and payers. It will allow us to expand affordable access to larger patient pools in these Emerging Markets, thus enabling equitable access to high quality biosimilars.”
The Company is addressing the challenge of insulin inequity in many Emerging Markets through its affordable and high-quality biosimilar insulins, where Recombinant Human Insulin and Insulin Glargine hold a dominant market share in countries like Mexico, Malaysia, Dominican Republic, Malawi, Tanzania, Mozambique etc.
The Company’s biosimilars are also making cancer care affordable for patients. Its portfolio compromising Trastuzumab, Bevacizumab and Pegfilgrastim is currently benefiting patients across United States, Canada, Europe and many Emerging Markets. Pegfilgrastim is among the leading biosimilars in its segment with a double-digit market share in the United States. Trastuzumab is among the leading biosimilars in its category in several APAC, AFMET and LATAM countries.
Biocon Biologics is providing affordable access to patients, prescribers, healthcare systems and governments through its unique portfolio of 8 commercialized biosimilars: Insulin Glargine, Insulin Aspart, recombinant Human Insulin, Trastuzumab, Bevacizumab, Pegfilgrastim, Adalimumab and Etanercept.
As a fully, vertically integrated lab-to-market player with global capabilities and a rich portfolio, Biocon Biologics is poised to make a meaningful difference to healthcare and patients’ lives worldwide.
About Biocon Biologics Limited:
Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives by enabling affordable access to high quality biosimilars for millions of patients worldwide. It is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. BBL has acquired the global biosimilars business of its long-standing partner Viatris, which is a historic milestone in its value creation journey. Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. The Company has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. It has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, BBL is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website: www.bioconbiologics.com; Follow us on Twitter: @BioconBiologics and LinkedIn: Biocon Biologics for company updates.
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com; Follow-us on Twitter: @bioconlimited for company updates.
Download Press Release